Reduced pten protein expression and its prognostic implications in canine and feline mammary tumors

Veterinary Pathology

Volumn 46, Issue 5, 2009, Pages 860-868

  Ressel, L ^a   Millanta, F ^a   Caleri, E ^a   Innocenti, V M ^a   Poli, A ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cats; Dogs; Mammary tumors; Overall survival; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CARCINOMA; CAT; CAT DISEASE; DOG; DOG DISEASE; EXPERIMENTAL NEOPLASM; FEMALE; FOLLOW UP; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR RECURRENCE;

ANIMALS; CARCINOMA; CAT DISEASES; CATS; DOG DISEASES; DOGS; FEMALE; FOLLOW-UP STUDIES; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MAMMARY NEOPLASMS, ANIMAL; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PTEN PHOSPHOHYDROLASE;

CANIS FAMILIARIS; FELIDAE; PYRONIA TITHONUS;

EID: 77149136791     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1354/vp.08-VP-0273-P-FL     Document Type: Article

References (41)

1. Azim H, Azim HA Jr: Targeting Her-2/neu in breast cancer: as easy as this! Oncology 74:150-157, 2008
2. Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R: Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 33:405-409, 2002
3. Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, Fusco A, Viglietto G: PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 19:3146-3155, 2000
4. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8:187-198, 2008
5. Castagnaro M, Casalone C, Bozzetta E, De Maria R, Biolatti B, Caramelli M: Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. J Comp Path 119:263-275, 1998
6. Chen J, Lindblom P, Lindblom A: A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet 102:124-125, 1998
7. Dahia PL: PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 7:115-129, 2000
8. Depowski PL, Rosenthal SI, Ross JS: Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14:672-676, 2001
9. Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 100:387-390, 2000
10. Dickerson EB, Thomas R, Fosmire SP, Lamerato-Kozicki AR, Bianco SR, Wojcieszyn JW, Breen M, Helfand SC, Modiano JF: Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. Vet Pathol 42:618-632, 2005
11. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991; republished Histopathology 41: 154-161, 2002
12. Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboue B, Latham WC, Eng C, Mulligan LM, Longy M: Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79:718-723, 1999
13. Fleming TR, Lin DY: Survival analysis in clinical trials: past developments and future directions. Biometrics 56:971-983, 2000
14. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, Liu X, Wu H: PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3:117-130, 2003
15. Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, España P, Bonilla F: Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 57:237-243, 1999
16. Garcia-Echeverria C, Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27:5511-5526, 2008
17. Kanae Y, Endoh D, Yokota H, Taniyama H, Hayashi M: Expression of the PTEN tumor sup-pressor gene in malignant mammary gland tumors of dogs. Am J Vet Res 67:127-133, 2006
18. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A: Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J Comp Pathol 133:246-252, 2005
19. Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF: Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol 39:458-472, 2002
20. Kotelevets L, van HJ, Bruyneel E, Mareel M, van RF, Chastre E: The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J Cell Biol 155: 1129-1135, 2001
21. Kotelevets L, van HJ, Bruyneel E, Mareel M, van RF, Chastre E: Implication of the MAGI1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. FASEB J 19:115-117,2005
22. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C: Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158:2097-2106, 2001
23. Levine RA, Forest T, Smith C: Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol 39:372-378, 2002
24. Maehama T, Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375-13378, 1998
25. Mikhail M, Velazquez E, Shapiro R, Berman R, Pavlick A, Sorhaindo L, Spira J, Mir C, Panageas KS, Polsky D, Osman I: PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 11:5153-5157, 2005
26. Misdorp W: Histological Classification of Mammary Tumors of the Dog and the Cat, AFIP, WHO, Washington, DC, 1999
27. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155:1253-1260, 1999
28. Planchon SM, Waite KA, Eng C: The nuclear affairs of PTEN. J Cell Sci 121:249-253, 2008
29. Qiu C, Lin D, Wang J, Wang L: Expression and significance of PTEN in canine mammary gland tumours. Res Vet Sci 85:383-388, 2008
30. Qiu CW, Lin DG, Wang JQ, Li CY, Deng GZ: Expression and significance of PTEN and VEGF in canine mammary gland tumours. Vet Res Commun 32:463-472, 2008
31. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner HH: PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57:4187-4190,1997
32. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57:3657-3659,1997
33. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M: PTEN gene alterations in lymphoid neoplasms. Blood 92:3410-3415, 1998
34. Shi W, Zhang X, Pintilie M, Ma N, Miller N, Banerjee D, Tsao MS, Mak T, Fyles A, Liu FF: Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer 104:195-203, 2003
35. Tamguney T, Stokoe D: New insights into PTEN. J Cell Sci 120:4071-4079, 2007
36. Tamura M, Gu J, Tran H, Yamada KM: PTEN gene and integrin signaling in cancer. J Natl Cancer Inst 91:1820-1828, 1999
37. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57:3935-3940, 1997
38. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S, Mori M: Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 68:398-404, 2005
39. Weijer K, Hart AA: Prognostic factors in feline mammary carcinoma. J Natl Cancer Inst 70:709-716,1983
40. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL: Inactivation of the tumor suppressor PTEN/ MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95:5246-5250, 1998
41. Winter JL, Stackhouse BL, Russell GB, Kute TE: Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer. Arch Pathol Lab Med 131:767-772, 2007